GlassScriptPhysician profile
Fayyaz U Haq
NPI 1144319567
$7,980.78
in general payments reported to CMS, 2019-2025
48 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $580 · 2021: $548 · 2022: $644 · 2023: $1,130 · 2024: $1,786 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,844 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,844.12 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $851.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $749.03 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $744.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $724.88 | 2019-2025 | |
| Amgen INC. | $410.40 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.65 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Abbvie INC. | $398.05 | 2019-2025 | |
| Glaxosmithkline, LLC. | $309.21 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.93 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $257.79 | 2019-2025 | |
| Astellas Pharma US INC | $248.63 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $235.93 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $209.63 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $194.23 | 2019-2025 | |
| Inspire Medical Systems, INC. | $182.26 | 2024-2025 | Inspire |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $161.36 | 2020-2024 | Verquvo, Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $134.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $118.51 | 2022-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $117.11 | 2024-2025 | Gemtesa |
| Amarin Pharma, INC. | $111.76 | 2019-2021 | |
| Horizon Therapeutics Plc | $101.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.98 | 2020-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $68.17 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $64.91 | 2024 | Voquezna |
| Abbott Laboratories | $61.28 | 2019-2023 | Freestyle Libre 2 |
| Shield Therapeutics INC | $60.21 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $59.48 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $53.64 | 2020-2024 | Nuzyra |
| Allergan, INC. | $51.95 | 2019-2020 | |
| Boston Scientific Corporation | $43.49 | 2025 | General - Pain Management |
| Vifor Pharma, INC. | $43.40 | 2019 | |
| Viiv Healthcare Company | $40.73 | 2023-2024 | Apretude |
| Sanofi Pasteur INC. | $39.57 | 2022-2023 | |
| Hologic Sales and Service, LLC | $34.27 | 2022-2023 | Aptima |
| Lundbeck LLC | $34.16 | 2024 | Rexulti |
| Dynavax Technologies Corporation | $34.07 | 2024 | Heplisav-B |
| Biohaven Pharmaceuticals, INC. | $29.53 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $29.06 | 2019 | |
| Edwards Lifesciences Corporation | $27.38 | 2025 | Sapien 3 Ultra Resilia |
| Biogen, INC. | $26.81 | 2025 | Leqembi |
| Calliditas Therapeutics US INC. | $24.68 | 2025 | Tarpeyo |
| Valeritas, INC. | $23.47 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.93 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.71 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $20.29 | 2025 | Uptravi, Opsumit |
| Nabriva Therapeutics, Plc | $19.32 | 2020 | |
| Idorsia Pharmaceuticals US INC | $18.71 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fayyaz Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.